LFCR Lifecore Biomedical Inc
Price (delayed)
$5.29
Market cap
$195.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$317.75M
Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for
Highlights
Lifecore Biomedical's net income has soared by 80% YoY
LFCR's EPS has soared by 79% YoY
Lifecore Biomedical's debt has increased by 9% YoY but it has decreased by 4% from the previous quarter
Key stats
What are the main financial stats of LFCR
Market
Valuations
Earnings
Shares outstanding
37.03M
Market cap
$195.86M
Enterprise value
$317.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
10.58
Price to sales (P/S)
1.39
EV/EBIT
46.47
EV/EBITDA
20.69
EV/Sales
2.43
Revenue
$130.86M
Gross profit
$45.64M
Operating income
-$12.29M
Net income
-$14.25M
EBIT
$6.84M
EBITDA
$15.36M
Free cash flow
-$14.4M
Per share
Balance sheet
Liquidity
EPS
-$0.5
EPS diluted
-$0.56
Free cash flow per share
-$0.42
Book value per share
$0.5
Revenue per share
$3.81
TBVPS
$6.91
Total assets
$255.39M
Total liabilities
$195.63M
Debt
$131.34M
Equity
$15.45M
Working capital
$46.57M
Debt to equity
8.5
Current ratio
2.32
Quick ratio
1.13
Net debt/EBITDA
7.94
Margins
Efficiency
Dividend
EBITDA margin
11.7%
Gross margin
34.9%
Net margin
-10.9%
Operating margin
-9.4%
Return on assets
-6.5%
Return on equity
-161.8%
Return on invested capital
2.1%
Return on capital employed
3.1%
Return on sales
5.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LFCR stock price
How has the Lifecore Biomedical stock price performed over time
Intraday
-22.32%
1 week
-22.77%
1 month
-9.11%
1 year
-13.56%
YTD
-28.8%
QTD
-24.86%
Financial performance
How have Lifecore Biomedical's revenue and profit performed over time
Revenue
$130.86M
Gross profit
$45.64M
Operating income
-$12.29M
Net income
-$14.25M
Gross margin
34.9%
Net margin
-10.9%
Lifecore Biomedical's net margin has soared by 83% YoY
Lifecore Biomedical's net income has soared by 80% YoY
Lifecore Biomedical's gross profit has surged by 57% YoY and by 2.5% QoQ
LFCR's operating margin has soared by 55% YoY but it is down by 2.2% from the previous quarter
Growth
What is Lifecore Biomedical's growth rate over time
Valuation
What is Lifecore Biomedical stock price valuation
P/E
N/A
P/B
10.58
P/S
1.39
EV/EBIT
46.47
EV/EBITDA
20.69
EV/Sales
2.43
LFCR's EPS has soared by 79% YoY
LFCR's P/B is 27% below its 5-year quarterly average of 14.5
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 2.6 and 18% lower than the last 4 quarters average of 1.7
LFCR's revenue is up by 16% YoY
Efficiency
How efficient is Lifecore Biomedical business performance
Lifecore Biomedical's return on invested capital has surged by 112% YoY but it has shrunk by 75% QoQ
LFCR's ROS has soared by 111% YoY but it has shrunk by 74% QoQ
Lifecore Biomedical's ROE has soared by 90% YoY
The ROA has soared by 78% YoY
Dividends
What is LFCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LFCR.
Financial health
How did Lifecore Biomedical financials performed over time
LFCR's total assets is 31% more than its total liabilities
The company's quick ratio rose by 49% QoQ and by 36% YoY
The company's current ratio rose by 27% QoQ and by 21% YoY
The debt to equity has soared by 124% QoQ but it has shrunk by 90% YoY
Lifecore Biomedical's debt has increased by 9% YoY but it has decreased by 4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.